New Data on Gene Therapy for Knee Osteoarthritis from Investing.com

TAMPA, Fla. – Pacira BioSciences, Inc. (NASDAQ: PCRX), one of the non-opioid drug treatment specialists, may conduct the presentation of new data on gene therapy candidates PCRX-201 on the existing ACR convergence tag. The Veranstaltung, organized by the American College of Rheumatology, took place from November 14 to 19 in Washington, DC statt.

The presentation entitled “Anhaltende Klinische Wirkungen nach einzigen intraartikulären Injektion von PCRX-201 bei mittelschwerer bis schwerer Kneearthrosis” on Sunday, November 17, from 10:30 AM to 12:30 PM EST by Dr. Stanley Cohen, a zertifizierten Rheumatologists, contents.

PCRX-201 is a locally expanded gene therapy for the production of interleukin-1 receptor antagonists (IL-1Ra). The soul is that Schmerzen are reducing and increasing the strength of the Knee Arthrosis through the modulation of the response to desire cooperation. The therapy appeared in March 2024 by the US Food and Drug Administration (FDA) and the Bezeichnung Regenerative Medicine Advanced Therapy (RMAT), was its potential as a significant improvement in arthrosis therapy. The European publication of the publication of Advanced Therapy Medicinal Products (ATMP) was published in May 2023.

Paciras Portfolio is one of the fastest growing commercially available non-opioid treatments: EXPAREL, ZILRETTA and other non-opioid treatments: EXPAREL, ZILRETTA and other non-opioid treatments from PCRX-201. The exchange of medicines is an initiative of a Breiteren, alternative medicine to opioids in the Schmerzmanagement of establishments.

In other cases, DOMA Perpetual Capital Management LLC has made an aggressive push into stock trading, driving up shareholder value. Der Umsatz von Pacira im ersten Quartal 2024 betrug 149 Millionen US-Dollar, wobei Exparel 118 Millionen US-Dollar beisteuerte. If a US$250 million walk in the world ends by the fall of 2029, it will post a US$242 million net profit.

Pacira’s analyst analysis was not done well. Jefferies has kept the Kursziel system in place through NOPAIN. It appears that the company has been legitimately backed by HC Wainwright, RBC Capital, Raymond James and Piper Sandler companies.

InvestingPro Insights

Pacira BioSciences has achieved a market capitalization of US$636.55 million. Das Kurs-Gewinn-Verhältnis (KGV) was 10.15, which was perhaps a big surprise in the representation of the underlying Gewinnen.

InvestingPro-Tipps said that management was active during the life of the company was often a signal in the interpretation of the Zukunft-saussichten-world. Analysts predict annual profitability and net profit figures.

The strong free cash flow returns of the developing world have entered the market, Barmittel will generate more cash and take more financial initiatives. The liquid assets that caused the first evaporation were a financial flexibility.

Trotz eines Kursrückgangs von 49.62% in de letzten drei Monaten kan och op die nogen op de noge opposeren, die glauben vortebrückschlag van de Unternehmens glauben. If you’re on the beach, Pacira won’t pay dividends.

For a good analysis, you can check out InvestingPro together with Pacira BioSciences at https://de.investing.com/pro/PCRX. This information can help significantly increase the risks and opportunities of investing in Pacira BioSciences, while increasing the company’s innovation in Schmerz’s innovative management.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.